Cantor Fitzgerald Weighs in on Krystal Biotech, Inc.’s FY2024 Earnings (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Cantor Fitzgerald lowered their FY2024 earnings estimates for Krystal Biotech in a note issued to investors on Monday, July 29th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn $2.92 per share for the year, down from their prior estimate of $4.00. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.00 per share.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. The company’s revenue was up 452400.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.76) EPS.

Several other equities analysts have also commented on KRYS. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday, May 6th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and a consensus price target of $177.63.

Krystal Biotech Trading Down 4.6 %

NASDAQ KRYS opened at $198.78 on Wednesday. The company’s 50-day moving average price is $184.55 and its 200-day moving average price is $162.86. The stock has a market cap of $5.68 billion, a PE ratio of 106.30 and a beta of 0.84. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in the stock. Fiera Capital Corp grew its stake in Krystal Biotech by 0.8% in the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after acquiring an additional 130 shares during the period. Rhumbline Advisers grew its stake in Krystal Biotech by 123.3% in the 2nd quarter. Rhumbline Advisers now owns 71,685 shares of the company’s stock valued at $13,164,000 after acquiring an additional 39,586 shares during the period. CIBC Asset Management Inc acquired a new stake in Krystal Biotech in the 2nd quarter valued at $250,000. Privium Fund Management B.V. grew its stake in Krystal Biotech by 42.7% in the 2nd quarter. Privium Fund Management B.V. now owns 6,420 shares of the company’s stock valued at $1,140,000 after acquiring an additional 1,920 shares during the period. Finally, Maryland State Retirement & Pension System acquired a new stake in Krystal Biotech in the 2nd quarter valued at $1,591,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).